Hui-Min Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hui-Min Li has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Guolin Chen1 shared publication
- Lei Shen
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China
1 shared publication Min-Xiu Tian
Renmin Hospital of Wuhan University, Hubei Key Laboratory of Digestive System Disease, Wuhan, Hubei 430060, P.R. China
1 shared publication- Shanshan Wang
National Key Laboratory of Plant Molecular Genetics, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China
1 shared publication - Shiqi Jia
The First Affiliated Hospital of Jinan University, Guangzhou, China
1 shared publication - Shuai Peng
State Key Laboratory of Plant Diversity and Specialty Crops; Wuhan Botanical Garden; Chinese Academy of Sciences; Wuhan 430074; China; Sino-Africa Joint Research Center; Chinese Academy of Sciences; Wuhan 430074; China
1 shared publication
Latest Publications
- Open Access
- 29 July 2023
- Published by Elsevier in Journal of Functional Foods
- Vol. 107
Lycium barbarum polysaccharides alleviate pancreatic β-cells apoptosis through the inhibition of IFNγ pathway
- 29 July 2023
- Published by Elsevier in Journal of Functional Foods
- Vol. 107
Open AccessLycium barbarum polysaccharides alleviate pancreatic β-cells apoptosis through the inhibition of IFNγ pathway
- Open Access
- 10 December 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (2) , 1
Poly(ADP‑ribose) polymerase‑1 inhibitor ameliorates dextran sulfate sodium‑induced colitis in mice by regulating the balance of Th17/Treg cells and inhibiting the NF‑κB signaling pathway
Poly(ADP‑ribose) polymerase‑1 (PARP‑1) plays a critical role in inflammatory pathways. The PARP‑1 inhibitor, 5‑aminoisoquinolinone (5‑AIQ), has been demonstrated to exert significant pharmacological effects. The present study aimed to further examine the potential mechanisms of 5‑AIQ in a mouse model of dextran sodium sulfate (DSS)‑induced colitis. Colitis conditions were assessed by changes in weight, disease activity index, colon length, histopathology and pro‑inflammatory mediators. The colonic expression of PARP/NF‑κB and STAT3 pathway components was measured by western blot analysis. Flow cytometry was used to analyze the proportion of T helper 17 cells (Th17) and regulatory T cells (Tregs) in the spleen. Western blot analysis and reverse transcription‑quantitative PCR were employed to determine the expression of the transcription factors retinoic acid‑related orphan receptor and forkhead box protein P3. The results demonstrated that 5‑AIQ reduced tissue damage and the inflammatory response in mice with experimental colitis. Moreover, 5‑AIQ increased the proportion of Treg cells and decreased the percentage of Th17 cells in the spleen. Furthermore, following 5‑AIQ treatment, the main components of the PARP/NF‑κB and STAT3 pathways were downregulated. Collectively, these results demonstrate that the PARP‑1 inhibitor, 5‑AIQ, may suppress intestinal inflammation and protect the colonic mucosa by modulating Treg/Th17 immune balance and inhibiting PARP‑1/NF‑κB and STAT3 signaling pathways in mice with experimental colitis.
- 10 December 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (2) , 1
Open AccessPoly(ADP‑ribose) polymerase‑1 inhibitor ameliorates dextran sulfate sodium‑induced colitis in mice by regulating the balance of Th17/Treg cells and inhibiting the NF‑κB signaling pathway
Poly(ADP‑ribose) polymerase‑1 (PARP‑1) plays a critical role in inflammatory pathways. The PARP‑1 inhibitor, 5‑aminoisoquinolinone (5‑AIQ), has been demonstrated to exert significant pharmacological effects. The present study aimed to further examine the potential mechanisms of 5‑AIQ in a mouse model of dextran sodium sulfate (DSS)‑induced colitis. Colitis conditions were assessed by changes in weight, disease activity index, colon length, histopathology and pro‑inflammatory mediators. The colonic expression of PARP/NF‑κB and STAT3 pathway components was measured by western blot analysis. Flow cytometry was used to analyze the proportion of T helper 17 cells (Th17) and regulatory T cells (Tregs) in the spleen. Western blot analysis and reverse transcription‑quantitative PCR were employed to determine the expression of the transcription factors retinoic acid‑related orphan receptor and forkhead box protein P3. The results demonstrated that 5‑AIQ reduced tissue damage and the inflammatory response in mice with experimental colitis. Moreover, 5‑AIQ increased the proportion of Treg cells and decreased the percentage of Th17 cells in the spleen. Furthermore, following 5‑AIQ treatment, the main components of the PARP/NF‑κB and STAT3 pathways were downregulated. Collectively, these results demonstrate that the PARP‑1 inhibitor, 5‑AIQ, may suppress intestinal inflammation and protect the colonic mucosa by modulating Treg/Th17 immune balance and inhibiting PARP‑1/NF‑κB and STAT3 signaling pathways in mice with experimental colitis.